← All trials
NCT03533712
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2018
- Primary completion
- May 31, 2021
- Completion date
- May 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 1776
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ghent UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
- Institut et Haute école de la Santé, La SourceCollaborator
- University of California, DavisCollaborator
- Bill and Melinda Gates FoundationCollaborator
- International Food Policy Research InstituteOverall official - principal investigator
- International Food Policy Research InstituteCollaborator
- Ghent UniversityReponsible party - principal investigator
- Ghent UniversityStudy chair
- Ghent UniversityStudy director
- Ghent UniversityOverall official - principal investigator
- AfricSanté, Burkina FasoCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.